S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
ASX:PAR

Paradigm Biopharmaceuticals (PAR) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
1.81 million shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PAR stock logo

About Paradigm Biopharmaceuticals Stock (ASX:PAR)

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.

PAR Stock News Headlines

Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
10 best makan places in Paradigm Mall JB
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Jaime King Signs With Paradigm
Paradigm Biopharmaceuticals Ltd PAR
See More Headlines
Receive PAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Paradigm Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
1,031
Year Founded
N/A

Profitability

Net Income
$-69,000,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$79,224.00
Book Value
A$0.10 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.92
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Paul John Rennie BSc (Age 65)
    Grad Dip, MBM, MSTC, Founder, MD & Executive Chairman
    Comp: $1.75M
  • Dr. Donna L. Skerrett M.D. (Age 67)
    MS, Chief Medical Officer and Executive Director
    Comp: $1.26M
  • Ms. Abby Macnish Niven B.Com.
    B.Sc., C.F.A., Interim Company Secretary & Interim CFO
  • Dr. Ravi Krishnan
    Chief Scientific Officer
  • Mr. Simon White
    Director of Investor Relations
  • Dr. Michael Imperiale
    Global Head of Drug Safety & MPS
  • Ms. Beverley Huttmann
    Commercial Head
  • Ms. Michelle Coffey
    Global Head of Regulatory Affairs
  • Dr. Mukesh Ahuja
    Global Clinical Head of OA

PAR Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Paradigm Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Paradigm Biopharmaceuticals investors own include BHP Group (BHP), Electro Optic Systems (EOS), First Graphene (FGR), Envirosuite (EVS), Bubs Australia (BUB), Blue Energy (BLU), BHP Group (BHP), Alcidion Group (ALC), a2 Milk (A2M) and 8common (8CO).

This page (ASX:PAR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners